Can blood and tumor samples predict who responds to brain cancer therapy?
NCT ID NCT06222138
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will collect blood and tumor samples from 80 people with newly diagnosed glioblastoma to find biological markers that show whether a treatment called TTFields (tumor-treating fields) is working. The goal is to understand why some patients respond and others don't. Participants will give samples before and during treatment, and researchers will track their outcomes for up to 24 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors predict which glioblastoma patients will benefit from TTFields therapy, leading to more personalized treatment plans.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find clear biomarkers, and results may not change patient care for years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IUCT-O
RECRUITINGToulouse, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?